Methods and compositions to enhance bone growth comprising a statin

Patent metadata

Field	Value
Publication number	US-9308190-B2
Application number	US-201213489173-A
Country	US
Kind code	B2
Filing date	Jun 5, 2012
Priority date	Jun 6, 2011
Publication date	Apr 12, 2016
Grant date	Apr 12, 2016

Abstract

Implantable medical devices and methods are provided that have one or more statins disposed therein. The medical devices may be implanted at near or in a bone defect to enhance bone growth. In some embodiments, the medical device provided allows for sustain release of the statin and facilitates bone formation and repair of the fracture site.

First claim

What is claimed is:

1. An implantable medical device configured to fit at, near or in a bone defect, the medical device comprising a biodegradable polymer, a therapeutically effective amount of a statin disposed throughout the medical device to facilitate bone growth, and trehalose, the polymer comprising poly(DL-lactide-co-glycolide), the medical device having an inherent viscosity of about 0.34 dL/g, the statin comprising at least cerivastatin, atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, rosuvastatin, eptastatin, pitavastatin, velostatin, fluindostatin, dalvastain, or pharmaceutically acceptable salts thereof or a combination thereof, wherein the medical device allows influx of at least progenitor, and/or bone cells at, near or in the bone defect.

2. An implantable medical device according to claim 1 , wherein the medical device comprises a drug depot capable of releasing an effective amount of a statin to facilitate bone formation within the bone defect.

3. An implantable medical device according to claim 2 , wherein the drug depot comprises a gel.

4. An implantable medical device according to claim 3 , wherein the gel is a hardening gel.

5. An implantable medical device according to claim 2 , wherein the drug depot comprises (i) one or more immediate release surfaces that has a burst release of about 5%, 10%, 15%, 20%, 25%, 30%, 35%, or 40% of the statin over 24 hours or 48 hours at, near or in the bone defect and (ii) one or more sustain release surfaces that releases an effective amount of the statin over a subsequent period of 3 to 6 weeks.

6. An implantable medical device according to claim 1 , wherein the medical device comprises an osteoconductive matrix.

7. An implantable medical device according to claim 6 , wherein the osteoconductive matrix comprises mineral particles dispersed therein.

8. An implantable medical device according to claim 7 , wherein the mineral particles comprise a cortical, cancellous, corticocancellous, allogenic, xenogenic or transgenic bone tissue, bone powder, demineralized bone powder, porous calcium phosphate ceramics, hydroxyapatite, tricalcium phosphate, bioactive glass or a combination thereof.

9. An implantable medical device according to claim 8 , wherein (i) the mineral particles comprise tricalcium phosphate and hydroxyapatite in a ratio of about 70:30 to about 90:10 or (ii) the mineral particles comprise tricalcium phosphate and hydroxyapatite in a ratio of about 85:15; or (iii) the mineral particles represent at least 50 to 98 weight percent of the medical device.

10. An implantable medical device according to claim 1 , wherein the matrix is freeze dried and rehydrated at the time of use.

11. An implantable medical device according to claim 1 , wherein the medical device has a volume of about 1 ml to about 5 ml.

12. An implantable medical device according to claim 1 , wherein the medical device releases about 1 mg to about 200 mg of the statin over between about 2 to about 4 weeks.

13. An implantable medical device according to claim 1 , wherein the medical device releases about 0.05 mg to about 10 mg per day of the statin or 1 mg to 20 mg over at least 4 weeks.

14. An implantable medical device according to claim 1 , wherein the statin is in the medical device in an amount of from 0.1 mg/cc to 100 mg/cc.

15. An implantable medical device according to claim 1 , wherein (i) the medical device releases 50%, 60%, 70%, 80%, 90%, 95%, 99%, or 100% of the statin loaded in the medical device over a period of 3 to 6 weeks after the device is administered thereto; (ii) the statin is encapsulated in microparticles, microspheres, microcapsules, and/or microfibers and distributed in the medical device; and (iii) the statin is encapsulated in nanoparticles, nanospheres, nanocapsules, and/or nanofibers and distributed in the medical device.

16. An implantable medical device according to claim 1 , wherein the statin is released in a daily dose of about 10 mcg/day to about 100 mcg/day.

17. An implantable medical device according to claim 1 , wherein the drug depot comprises a gel and has a pre-dose modulus of elasticity in the range of about 1×10 2 to about 3×10 5 dynes/cm 2 and a post-dose modulus of elasticity of about 1×10 2 to about 2×10 6 dynes/cm 2 .

Assignees

• Li Ping
• Marx Jeffrey C
• Mckay William F
• Warsaw Orthopedic Inc

Inventors

• Li Ping
• Marx Jeffrey C
• Mckay William F

Classifications

• A61K31/22 Primary

  of acyclic acids, e.g. pravastatin · CPC title

• A61K31/366 Primary

  having six-membered rings, e.g. delta-lactones · CPC title

• A61K47/22

  Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones · CPC title

• A61K31/40

  having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil · CPC title

• A61K33/42

  Phosphorus; Compounds thereof · CPC title